黄茂华,男,博士,副研究员。
2015年毕业于广州中医药大学中药学院,获学士学位。2021年毕业于暨南大学中药药理学专业,获博士学位。2021年7月进入暨南大学中西医结合博士后流动站进行博士后研究。2023年7月进入暨南大学药学院工作。主持国家自然科学基金青年基金项目、广东省自然科学基金-面上项目和广东省区域联合基金-青年基金项目各1项。已发表SCI论文27篇,其中以第一作者/共同第一作者发表的SCI论文13篇。参编英文著作1部,申请中国发明专利3项。
研究方向:
1)中药和天然药物的抗肿瘤活性成分筛选、作用机制研究以及相关创新药物的研发
2)周细胞介导肿瘤耐药和转移的新机制研究和周细胞靶向药物研发
教学工作:参与讲授研究生课程《天然活性成分提取分离和筛选新技术》
主持的科研项目:
[1] 国家自然科学基金青年基金项目(项目编号:82204427, 主持)
[2] 广东省自然科学基金-面上项目(项目编号: 2023A1515010361,主持)
[3] 广东省区域联合基金-青年基金项目(项目编号: 2021A1515110242,主持)
代表性论文:
[1] Huang MH#, Lin YN#, Wang CR#, Deng LJ, Chen MF, Yehuda G. Assaraf, Chen ZS*, Ye WC*, Zhang DM*. New insights into antiangiogenic therapy resistance in cancer: mechanisms and therapeutic aspects. Drug Resist Updat, 2022;64:100849.
[2] Wang CR#, Huang MH#, Lin YN#, Zhang YM, Pan JH, Jiang C, Cheng MJ, Li SR, He WZ, Li ZQ, Tu ZC, Fan J, Zeng HH, Lin JH, Wang YJ, Yao N, Liu TZ, Qi Q, Liu XN, Zhang ZM, Chen MF*, Xia LP*, Zhang DM*, Ye WC*. ENO2-derived phosphoenolpyruvate functions as an endogenous inhibitor of HDAC1 and confers resistance to antiangiogenic therapy. Nat Metab, 2023;10.1038/s42255-023-00883-y
[3] Huang MH#, Chen MF#, Qi M, Ye GN, Pan JH, Shi CZ, Yang YL, Zhao LY, Mo XK, Zhang YR, Li Y, Zhong JC, Lu WJ, Li XB, Zhang JY, Lin JR, Luo LP, Liu TZ, Tang P. M-K, Hong A, Cao YH*, Ye WC*, Zhang DM*. Perivascular cell-derived extracellular vesicles stimulate colorectal cancer revascularization after withdrawal of antiangiogenic drugs. J Extracell Vesicles, 2021;10(7):e12096.
[4] Wen Q#, Huang MH#, Xie JW#, Liu RY#, Miao Q, Huang JJ, Zhang JQ, Lyu WY, Qi M, Wu CY, Qi Q, Zhang ZJ, Deng R, Wang CR, Chen ZS*, Zhang DM*, Ye WC*, Chen MF*. lncRNA SYTL5-OT4 promotes vessel co-option by inhibiting the autophagic degradation of ASCT2. Drug Resist Updat, 2023;69:100975.
[5] Qi M#, Fan SR#, Huang MH#, Pan JH, Li Y, Miao Q, Lyu WY, Li XB, Deng LJ, Qiu SH, Liu TZ, Deng WQ, Chu XD, Jiang C, He WZ, Xia LP, Yang YL, Hong J, Qi Q, Yin WQ, Liu XN, Shi CZ, Chen MF*, Ye WC*, Zhang DM*. Targeting FAPα-expressing hepatic stellate cells overcomes resistance to antiangiogenics in colorectal cancer liver metastasis models. J Clin Invest, 2022;132(19):e157399.
[6] Huang MH#, Liu MQ#, Huang DD#, Ma YP, Ye GN, Wen Q, Li Y, Deng LJ, Qi Q, Liu TZ, Liu XN, Chen MF*, Ye WC*, Zhang DM*. Tumor perivascular cell-derived extracellular vesicles promote angiogenesis via the Gas6/Axl pathway. Cancer Lett, 2022;524:131-143.
[7] Ye GN#, Huang MH#, Li Y, Ouyang J, Chen MF, Wen Q, Li XB, Zeng HH, Long P, Fan ZP, Yin JQ*, Ye WC*, Zhang DM*. The FAPα-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the Axl pathway. Acta Pharm Sin B, 2022;12(3):1288-1304.
[8] Huang MH#, Qi M#, Yang HY#, Peng Z, Chen SG, Liang MC, Hu YZ*, Deng LJ*, Hu M*. Noninvasive strategies for the treatment of tiny liver cancer: integrating photothermal therapy and multimodality imaging EpCAM-guided nanoparticles. ACS Appl Mater Interfaces, 2023;15(18):21843-21853.
[9] Wang S#, Huang MH#, Chen MF#, Sun ZT#, Jiao YB, Ye GN, Pan JH, Ye WC*, Zhao JF*, Zhang DM*. Zoledronic acid and thymosin α1 elicit antitumor immunity against prostate cancer by enhancing tumor inflammation and cytotoxic T cells.J Immunother Cancer, 2023;11(6):e006381.
[10] Lin JP#, Huang MH#, Sun ZT#, Chen L, Lei YH, Huang YQ, Qi M, Fan SR, Chen SG, Chung CW, Chan MC, Liu JS, Hu M, Chen MF, Ye WC, Chen YY*, Deng LJ*. Periplocin inhibits hepatocellular carcinoma progression and reduces the recruitment of MDSCs through AKT/NF-κB pathway. Life Sci, 2023;324:121715.
[11] Sun HY#, Huang MH#, Yao N#, Hu JY, Li YJ, Chen LP, Hu N, Ye WC, Tai W. C-S, Zhang DM*, Chen SB*. The cycloartane triterpenoid ADCX impairs autophagic degradation through Akt overactivation and promotes apoptotic cell death in multidrug-resistant HepG2/ADM cells. Biochem Pharmacol, 2017;146:87-100.